Scientific program

Session Key:

Pre-Congress Workshop Plenary Session Parallel Session Free Papers Session Industry Symposium

Thursday, October 13, 2022

08:30-11:30 Pre-Congress Workshop 1:
Breast cancer in young women: Understanding differences to optimise outcomes
Hall A
(Great Hall 1)
Chairpersons Sanjeev Kumar, Sydney, Australia
Jenny Gilchrist, Sydney, Australia
08:30-09:00 Fertility and breast cancer
Ying Li, Sydney, Australia
09:00-09:30 Management of menopausal side effects
Martha Hickey, Melbourne, Australia
09:30-10:00 Goserelin (Zoladex) in young women
Prudence Francis, Melbourne, Australia
10:00-10:20 Coffee Break 
10:20-11:10 The art of oncology: Treating young women with a focus on pregnancy after breast cancer
Ann Partridge, Boston, MA, USA
11:10-11:30 Q&A

 

 08:30-11:30 Pre-Congress Workshop 2:
Contrast based breast imaging
Hall C
(Room M1)
Chairperson Nick Repin, Lismore, Australia
08:30-08:35 Welcome
Nick Repin, Lismore, Australia
08:35-08:55 Implementation of Contrast Imaging: Challenges and opportunities
Allison Rose,
Melbourne, Australia
08:55-09:40 Indications for Contrast Imaging
Julia Camps Herrero,
Valencia, Spain
09:40-10:00 Contrast Enhanced Mammography (CEM) in surveillance
Allison Rose,
Melbourne, Australia
10:00-10:30 Coffee Break 
10:30-11:30 MDM hypothetical-case presentations and discussions
Julia Camps Herrero, Valencia, Spain
Allison Rose,
Melbourne, Australia
Bruce Mann, Melbourne, Australia
Michael Christie, Melbourne, Australia

 

 08:30-11:30 Pre-Congress Workshop 3:
Bioethical dilemmas: Q&A, cases and discussion
Hall D
(Room M2)
Chairperson Jennifer O’Sullivan, Sydney, Australia
08:30-10:00 Cases and discussion
David Kirchhoffer, Brisbane, Australia
Bridget Pratt, Brisbane, Australia
10:00-10:20 Coffee Break 
10:20-11:30 Cases and discussion contd.

 

11:30-12:30 Lunch Break 

 

 12:30-15:30 Pre-Congress Workshop 4:
Hereditary breast cancer
Hall A
(Great Hall 1)
Chairperson Nirmala Pathmanathan, Sydney, Australia 
12:30-13:20 Management of common genetic predisposition syndromes
Milita Zaheed, Sydney, Australia
13:20-14:00 The “extended panel” of genetic testing; implications and management
Helen Mar Fan, Brisbane, Australia
14:00-14:20 Coffee Break 
14:20-14:55 Molecular mechanisms, diagnostic and therapeutic implications of hereditary breast cancer syndromes
Sunil Lakhani, Brisbane, Australia
14:55-13:20 Psychological impact and management of patients with hereditary breast cancer
Jemma Gilchrist, Sydney, Australia

 

12:30-15:30 Pre-Congress Workshop 5:
Radiation oncology: Clinical updates and clinical challenges
Hall C
(Room M1)
Chairperson Marcus Dreosti, Adelaide, Australia 
12:30-13:15 Frank A. Vicini, Royal Oak, MI, USA
13:15-14:00 Boon Chua, Sydney, Australia
14:00-14:20 Coffee Break 
14:20-15:30 Q&A

 

12:30-15:30 Pre-Congress Workshop 6:
Challenging communication
Hall D
(Room M2)
Chairperson Jenny Gilchrist, Sydney, Australia
12:30-14:00 Cases and discussion
Jane Turner,
Brisbane, Australia
14:00-14:20 Coffee Break 
14:20-15:30 Cases and discussion contd.

 

15:30-16:00 Break 

 

16:00-16:15 Congress Opening Hall A
(Great Hall 1)
Chairperson: Bruce Mann, Melbourne, Australia
Welcome to Country
Welcome from Congress chairpersons

 

16:15-17:45 Plenary Session 1:
Neoadjuvant therapy
Hall A
(Great Hall 1)
Chairpersons Elisabeth Elder, Sydney, Australia
Richard de Boer,
Melbourne, Australia
 16:15-16:45
16:15
16:25
16:35
Debate: That cT1cN0 HER2+ve and TNBC should have NAST
Yes: Alistair Ring, London, UK
No: Nicholas Wilcken, Sydney, Australia
Discussion
16:45-17:15 Lessons learnt: The UK experience of Neo Adjuvant Endocrine Therapy (NAET) during the COVID-19 pandemic
Stephen Johnston, London, UK
 17:15-17:45
17:15
17:25
17:35
Debate: That LN positive patients achieving pCR with NAST should still receive regional nodal radiotherapy
Yes: Frank A. Vicini, Royal Oak, MI, USA
No: Steven David, Melbourne, Australia
Discussion

 

 17:45 Networking Reception

Friday, October 14, 2022

07:30-08:30 Morning Industry Symposium:
The role of Enhertu (trastuzumab-deruxtecan) in changing the treatment paradigm for HER2-positive Metastatic Breast Cancer
Supported by AstraZeneca
Please note breakfast will be served  prior to the session.
Hall A
(Great Hall 1)

 

07:30-08:30 Morning Industry Symposium:
DCISionRT: Personalising treatment for women with DCIS
Supported by GenesisCare and PreludeDX
Please note breakfast will be served  prior to the session.
Hall B
(Great Hall 2)

 

07:30-08:30 Morning Industry Symposium:
Risk adjusted screening
Supported by Hologic
Please note breakfast will be served  prior to the session.
Hall C
(Room M1)
 08:30-09:30 Parallel Session 2:
Screening
Hall A
(Great Hall 1)
 Chairpersons Allison Rose, Melbourne, Australia
Owen Ung,
Brisbane, Australia
08:30-08:45 Tailored screening: The Netherlands experience
Ritse Mann, Nijmegen, The Netherlands
 08:45-09:15
08:45
08:55
09:05
Debate: That women at low risk for breast cancer should only be screened every 5 years
Yes: Christobel Saunders, Melbourne, Australia
No: Jane Fox, Melbourne, Australia
Discussion
 09:15-09:30 Risk adjusted screening: Considerations and lessons from COVID-19
Carolyn Nickson, Melbourne, Australia

 

 08:30-09:30 Parallel Session 3:
Fear of cancer recurrence
Hall B
(Great Hall 2)
Chairpersons Kerry Shanahan, Melbourne, Australia
Belinda Yeo, Melbourne, Australia
08:30-08:50 Fear of cancer recurrence: What is it, and how common is it?
Jane Turner, Brisbane, Australia
08:50-09:10 Is it possible to conquer fear of recurrence?
Charlotte Tottman, Adelaide, Australia
09:10-09:30 Discussion

 

08:30-09:30 Industry Symposium:
Evolution of treatment sequencing in patients with mTNBC
Supported by Gilead
Hall C
(Room M1)

 

 09:30-11:00 Plenary Session 4:
Genetics
Hall A
(Great Hall 1)
 Chairpersons Nicole McCarthy, Brisbane, Australia
Jane Fox, Melbourne, Australia
 09:30-10:10
09:30
09:45
10:00
Debate: That ~all patients with breast cancer should be panel tested for germline mutations
Yes: Yoland Antill, Melbourne, Australia
No: Helen Mar Fan, Brisbane, Australia
Discussion
10:10-10:35 The ‘new genes’: What do they mean for patients and families?
Paul James, Melbourne, Australia
10:35-11:00 Tailored treatments for BRCA+ early breast cancer: The time is now!
Mark Robson, New York, NY, USA

 

11:00-11:30 Coffee break, poster viewing and exhibition visit

 

 11:30-12:30 Parallel Session 5:
Lymphoedema
Hall A
(Great Hall 1)
 Chairpersons Kerry Patford, Benalla, Australia
Rajiv Dave, Manchester, UK
 11:30-11:50 What is the evidence behind advice regarding lymphoedema prevention?
Louise Koelmeyer, Sydney, Australia
11:50-12:10 Evidence based treatment modalities for established lymphoedema: What works? What doesn’t?
Robyn Box, Brisbane, Australia
 12:10-12:30 Discussion

 

11:30-12:30 Industry Symposium:
Improving outcomes in high-risk HER2-positive patients post-KATHERINE
Supported by an educational/research sponsorship by Roche
Hall B
(Great Hall 2)

 

 11:30-12:30 Industry Symposium:
Touch and go: Removing the guesswork in detecting residual cancer
Supported by OncoRes
Hall C
(Room M1)

 

12:30-13:30 Lunch break, poster viewing and exhibition visit

 

 13:30-14:30 Parallel Session 6:
DCIS
Hall A
(Great Hall 1)
 Chairpersons Steven David, Melbourne, Australia
Caroline Baker,
Melbourne, Australia
 13:30-14:00
13:30
13:40
13:50
Debate: That most patients with DCIS should have radiotherapy after Breast Conserving Surgery
Yes: Boon Chua, Sydney, Australia
No: Alastair Thompson, Houston, TX, USA
Discussion
14:00-14:30
14:00
14:10
14:20
Debate: That active surveillance for low risk DCIS is a reasonable option
Yes: Jocelyn Lippey, Melbourne, Australia
No: Heidi Peverill, Brisbane, Australia
Discussion

 

13:30-14:30 Parallel Session 7:
Triple negative breast cancer

Hall B
(Great Hall 2)
 Chairpersons Nicholas Wilcken, Sydney, Australia
Catherine Shannon, Brisbane, Australia
13:30-14:10
13:30
13:45
14:00
Debate: Immunotherapy should be part of standard of care in neoadjuvant treatment for TN ESBC
Yes: Javier Cortes, Madrid, Spain
No: Alistair Ring, London, UK
Discussion
14:10-14:30 TNBC subtypes and their clinical significance
Nirmala Pathmanathan, Sydney, Australia

 

 13:30-14:30 Parallel Session 8:
Free Papers: Supportive care
Hall C
(Room M1)
 Chairpersons Yoland Antill, Melbourne, Australia
Marissa Stevens, Melbourne, Australia
13:30-13:40 “Linking risk with screening” – the impact of an online decision aid for risk-stratified breast screening on understanding, acceptance and decision-making
Jocelyn Lippey, Melbourne, Australia
13:40-13:50 What is women with breast cancers’ experience and perception of genitourinary symptoms?
Antonia Pearson, Sydney, Australia
13:50-14:00 Estimating end of life care costs to different funders for breast cancer patients in Queensland, Australia: A data linkage study
Shafkat Jahan, Brisbane, Australia
14:00-14:10
Supporting LGBTQI communities impacted by breast cancer: Results and translational  outcomes of the out with cancer study
Julie Rae, Red Hill, Australia
14:10-14:20 Patient perceptions of physical rehabilitation and its method of delivery for a variety of adverse physical effects following breast cancer surgery
Deirdre McGhee, Wollongong, Australia
14:20-14:30
No association between breast pain and breast cancer. A prospective cohort study of 10,830 patients presenting to a Breast Cancer Diagnostic Clinic
Rajiv Dave, Manchester, UK

 

 14:30-15:50 Parallel Session 9:
Adjuvant endocrine therapy
Hall A
(Great Hall 1)
Chairpersons Prudence Francis, Melbourne, Australia
Richard de Boer
, Melbourne, Australia
14:30-15:05
14:30
14:40
14:50
Debate: That CDK4/6i’s should be part of adjuvant treatment of high risk ER+HER2- early breast cancer
Yes: Richard de Boer, Melbourne, Australia
No: Nick Zdenkowski, Newcastle, Australia
Discussion
15:05-15:15 Real world evidence and its value in breast cancer management?
Sheau Wen Lok, Melbourne, Australia
15:15-15:50
15:15
15:25
15:35
Debate: That all pre-menopausal women with LN+ve ER+HER2- EBC should have adjuvant chemotherapy
Yes: Nicole McCarthy, Brisbane, Australia
No: Belinda Yeo, Melbourne, Australia
Discussion

 

 14:30-15:50 Parallel Session 10:
Free Papers: Locoregional therapy
Hall C
(Room M1)
 Chairpersons Michael Alvarado, San Francisco, CA, USA
Jill Dietz, Pittsburgh, PA, USA
14:30-14:40 Outcome of atypical or b3 lesions in Breastscreen NSW
Richard Chou, Condell Park, Australia
14:40-14:50 Contrast Enhanced Mammography in further assessment of screen-detected breast cancer
Caroline MacCallum, Melbourne, Australia
14:50-15:00 Comparison of local recurrence after simple and skin-sparing mastectomy performed in patients with pure ductal carcinoma in situ
Rajiv Dave, Manchester, UK
15:00-15:10 Using Radio-Occult Lesion Localization (ROLL) techniques to identify the clipped node in Targeted Axillary Dissections (TAD)
Alec Winder, Townsville, Australia
15:10-15:20 Comparing direct-to-implant and two-stage breast reconstruction in the Australian breast device registry
Sheymonti Hoque, Melbourne, Australia
15:20-15:30 Trends and variations in post-mastectomy breast reconstruction rates in Australia over 10 years
Nirmal Dayaratna, Sydney, Australia
15:30-15:40 Surgical outcomes of post-mastectomy radiotherapy following immediate prosthetic breast reconstruction: Six-year experience
Negin Sedaghat, Sydney, Australia
15:40-15:50 Therapeutic mammaplasty with contralateral symmetrising reduction mammaplasty: Oncologically safe with satisfied patients
Susannah Graham, Camperdown, Australia

 

15:50-16:10 Coffee break, poster viewing and exhibition visit

 

 16:10-17:30 Parallel Session 11:
Imaging
Hall A
(Great Hall 1)
Chairpersons Jane Fox, Melbourne, Australia
Alastair Thompson, Houston, TX, USA
16:10-16:30 How can imaging assist management of patients receiving neoadjuvant therapy?
Julia Camps Herrero, Valencia, Spain
16:30-16:50 The PROSPECT of selective omission of RT based on MRI findings
Bruce Mann, Melbourne, Australia
16:50-17:10 That Contrast Enhanced Mammography (CEM) is ready for prime time
Allison Rose, Melbourne, Australia
17:10-17:30 Discussion

 

16:10-17:30 Parallel Session 12:
Metastatic breast cancer
Hall B
(Great Hall 2)
Chairpersons Nick Zdenkowski, Newcastle, Australia
Javier Cortes, Madrid, Spain
16:10-16:45
16:10
16:20
16:30
Debate: That molecular testing of tumours should be routine for patients with metastatic breast cancer
Yes: Elgene Lim, Sydney, Australia
No: TBA
Discussion
16:45-17:00 What’s the optimal timing for Bone Targeted Agents in MBC?
Belinda Yeo, Melbourne, Australia
17:00-17:30
17:00
17:10
17:20
Debate: Routine imaging vs clinical follow-up for high risk EBC: Time to change the paradigm?
Yes: Sally Baron-Hay, Sydney, Australia
No: Catherine Shannon, Brisbane, Australia
Discussion

 

Saturday, October 15, 2022

07:30- 08:30 Morning Industry Symposium:
Future-proofing breast surgical guidance with Sentimag®
A total magnetic conversion
Supported by Endomag/GRC Surgical
Please note breakfast will be served  prior to the session.
Hall A
(Great Hall 1)

 

07:30-08:30 Morning Industry Symposium:
Time to start CDK4&6 inhibition in EBC: Verzenio in HR+ HER2- node positive EBC at high risk of recurrence
Supported by Lilly
Please note breakfast will be served  prior to the session.
Hall B
(Great Hall 2)

 

07:30-08:30 Morning Industry Symposium:
The role of the nurse in assessing, triaging and managing metastatic TNBC
Supported by Gilead
Please note breakfast will be served  prior to the session.
Hall C
(Room M1)

 

 08:30-10:00 Parallel Session 13:
Controversies in reconstruction
Hall A
(Great Hall 1)
Chairpersons Kirsten Pilatti, Melbourne, Australia
Sanjay Warrier, Sydney, Australia
 08:30-09:10
08:30
08:40
08:50
Debate: That immediate breast reconstruction prior to post-mastectomy radiotherapy should be avoided
Yes: Caroline Baker, Melbourne, Australia
No: Dean Trotter, Melbourne, Australia
Discussion
 09:10-09:30 Patient-reported outcomes to guide decisions regarding breast reconstruction
Douglas MacMillan, Nottingham, UK
09:30-09:50 Consumer voice informing the future of breast reconstruction Australia
Sam Mills, Melbourne, Australia
Jodi Steel, Sydney, Australia
09:50-10:00 Discussion

 

 08:30-10:00 Parallel Session 14:
Survivorship
Hall B
(Great Hall 2)
 Chairpersons Jenny Gilchrist, Sydney, Australia
Jocelyn Lippey, Melbourne, Australia
08:30-08:35 Introduction
Jenny Gilchrist, Sydney, Australia
08:35-08:45 What matters most to consumers?
Andrea Smith,
Sydney, Australia
08:45-08:55 GP perspective
Elysia Thornton-Benko, Sydney, Australia
08:55-09:05 Survivorship MoC based around nurse led clinics
Kerry Shanahan, Melbourne, Australia
09:05-09:15 McGrath model of survivorship care
Kerry Patford, Benalla, Australia 
09:15-09:25 #JustTextMe: Empowering women’s health during survivorship
Anna Singleton, Sydney, Australia
09:25-09:35 IBIS
Raymond Chan, Adelaide, Australia
09:35-10:00 Discussion

 

 08:30-10:00 Parallel Session 15:
Free Papers: Medical oncology
Hall C
(Room M1)
Chairpersons Nick Zdenkowski, Newcastle, Australia
Sally Baron-Hay, Sydney, Australia
08:30-08:40 Update on the use of topical estrogens in symptomatic women with early breast cancer
Antonia Pearson, Sydney, Australia
08:40-08:50 Contrast Enhanced Mammography in breast cancer surveillance
Kenneth Elder, Melbourne, Australia
08:50-09:00 Contralateral breast cancer: Influence of molecular subtype, clinical features and treatment given in a single institution study
Mohammad Amira, Perth, Australia
09:00-09:10 The effect of age and menstrual cycling on gene expression profiling tests
Wendy Ingman, Adelaide, Australia
09:10-09:20 Concordance between core needle biopsy and surgical excision for breast cancer tumor grade and biomarkers
Aswin Shanmugalingam, Sydney, Australia
09:20-09:30 The design and development of an individualised training program for Metastatic Breast Cancer (MBC) nursing incorporating remote and onsite learning experiences during a pandemic
Gillian Kruss, Sydney, Australia
09:30-09:40 ATNEC – patient experience sub-study (IRSCTN: 36585784):
What patients think about taking part in breast cancer treatment de-escalation trials?
Janet Dunn, Coventry, UK
09:40-09:50 Monitoring of breast cancer treatment response by analysis of breast cancer-derived extracellular vesicles
Katherine Wongtrakul-Kish, Sydney, Australia
09:50-10:00 Enhanced toxicity with trastuzumab emtansine and concurrent adjuvant radiotherapy: Non-consecutive case series
Steven David,
Melbourne, Australia

 

 10:00-11:00 Parallel Session 16:
Locoregional therapy
Hall A
(Great Hall 1)
Chairpersons Heidi Peverill, Brisbane, Australia
Caroline Baker, Melbourne, Australia
10:00-10:30

10:00
10:10
10:20

Debate: That patients with heavy axillary nodal disease pre-NACT should have axillary dissection irrespective of response to NACT
Yes: Alastair Thompson, Houston, TX, USA
No: Ben Green, Brisbane, Australia
Discussion
 10:30-11:00
10:30
10:40
10:50
Debate: That omission of SNB should be considered for all women >70 with clinically negative axillae
Yes: Melanie Walker, Melbourne, Australia
No: Sanjay Warrier, Sydney, Australia
Discussion

 

10:00-11:00 Industry Symposium:
A CDK4/6i is a ‘once in a lifetime treatment’ for patients with HR +ve HER2 -ve breast cancer
Supported by Novartis
Hall B
(Great Hall 2)

 

11:00-11:30 Coffee break, poster viewing and exhibition visit

 

 11:30-13:00 Parallel Session 17:
Local therapy
Hall A
(Great Hall 1)
Chairpersons Christobel Saunders, Melbourne, Australia
Melanie Walker, Melbourne, Australia
11:30-12:30 Time to cut the wire?
 11:30 That hook needles are perfectly satisfactory for lesion localisation
Owen Ung, Brisbane, Australia
11:40 The case for SCOUT
Cindy Mak, Sydney, Australia
11:50 The case for Magseed
Michael Alvarado, San Francisco, CA, USA
12:00 The case for ROLLIS
Rhea Liang, Gold Coast, Australia
12:10 Discussion
12:30-13:00
12:30
12:40
12:50
Debate: That five-fraction radiotherapy should be standard of care for most patients
Yes: Alice Ho, Boston, MA, USA
No: Frank A. Vicini, Royal Oak, MI, USA
Discussion

 

11:30-13:00 Parallel Session 18:
HER2 positive disease
Hall B
(Great Hall 2)
Chairpersons Nicole McCarthy, Brisbane, Australia
Elgene Lim, Sydney, Australia
11:30-12:15
11:30
11:45
12:00
Debate: Do anthracyclines still have a place in the treatment of early stage HER2+ve BC?
Yes: Nick Murray, Adelaide, Australia
No: Fran Boyle, Sydney, Australia
Discussion
 12:15-12:35 HER2 heterogeneity: Interpretation of low HER2 amplification and HER+ve hotspots
Cameron Snell, Melbourne, Australia
 12:35-13:00 Management of brain mets in those with HER2+ve disease
Rebecca Dent, Singapore, Singapore

 

13:00-14:00 Lunch break, poster viewing and exhibition visit

 

13:10-13:55 Lunch Industry Symposium:
Innovative approaches to help improve patient outcomes: Case-based discussion
Supported by 3M
Lunch boxes will be served to session participants.
Hall B
(Great Hall 2)

 

10:30-17:00 Breast Cancer Network Australia 
Hall C (Room M1)

 

 14:00-15:00 Plenary Session 19:
Palliative care
Hall A
(Great Hall 1)
Chairpersons Fran Boyle, Sydney, Australia
Nick Murray, Adelaide, Australia
14:00-14:30
14:00
14:10
14:20
Debate: That palliative care should ditch the word ‘palliative’
Yes: Brian Le, Melbourne, Australia
No: Andrew Broadbent, Gold Coast, Australia
Discussion
14:30-15:00 Medicinal cannabis in advanced cancer: Pot or panacea?
Phillip Good, Brisbane, Australia

 

 15:00-16:15 Plenary Session 20:
Breast cancer 2030
Hall A
(Great Hall 1)
 Chairpersons Bruce Mann, Melbourne, Australia
Richard de Boer,
Melbourne, Australia
15:00-15:15 Early detection in 2030
Ritse Mann, Nijmegen, The Netherlands
15:15-15:30 A pathologist’s view of breast cancer in 2030
Sunil R. Lakhani, Brisbane, Australia
15:30-15:45 Systemic therapy in 2030
Prudence Francis, Melbourne, Australia
15:45-16:00 Locoregional therapy in 2030
Douglas MacMillan, Nottingham, UK
16:00-16:15 A consumer’s perspective of breast cancer in 2030
Kirsten Pilatti, Melbourne, Australia

 

16:15-16:30 Congress closing and Award presentation
Hall A
(Great Hall 1)
 Chairpersons Bruce Mann, Melbourne, Australia
Melanie Walker, Melbourne, Australia
Elisabeth Elder, Sydney, Australia

 

Skip to content